ObjectiveTandem mass spectrometry is used to observe the changes in amino acids level in peripheral blood of patients with chronic obstructive pulmonary disease (COPD) of different severity, and explore the related factors that affect the level of amino acids in COPD patients.MethodsA collection of 99 COPD patients from the First Affiliated Hospital of Jinzhou Medical University between May 2020 and August 2020 were divided into GOLD Ⅰ/Ⅱ group, GOLD Ⅲ group and GOLD Ⅳ group according to the results of their lung function. Thirty healthy physical examination subjects during the same period were enrolled as a healthy control group. Peripheral amino acids were detected by liquid chromatography-tandem mass spectrometry (LC-MS).ResultsThe metabolism of 11 amino acids was correlated with the onset of COPD and the disorder of amino acid metabolism became more significant with the aggravation of the disease, and branched-chain amino acids (leucine, valine) had statistically significant differences in the COPD patients with different GOLD grades (P<0.05 and VIP>1). The difference between glutamate and glutamine was statistically significant only in GOLD Ⅳ stage (P<0.05 and VIP>1). The content of tyrosine and phenylalanine gradually increased with the increase of disease severity, and had significant difference in GOLD stage Ⅳ (P<0.05).ConclusionsCOPD patients with different GOLD grades have obvious amino acid metabolism disorders, including insufficient intake of essential amino acids and increased amino acids related to muscle protein catabolism. Understanding the mechanism between amino acid metabolism and COPD may provide a new direction for the diagnosis and treatment of the disease.
ObjectiveTo investigate the bidirectional causal relationship between metabolic syndrome (MS) and inflammatory bowel disease (IBD) using Mendelian randomization (MR). MethodsWe extracted genetic variants with strong correlations from genome-wide association study data on MS as instrumental variables. Inverse variance weighting, MR-Egger regression methods, and weighted median methods were used to estimate the causal effect of MS and risk of developing IBD. ResultsInverse variance weighting found that genetically predicted MS was associated with an increased risk of developing IBD overall (OR=1.113, 95%CI 1.020 to 1.216, P=0.017) and Crohn's disease (OR=1.195, 95%CI 1.072 to 1.333, P=0.001). And inverse MR analysis found ulcerative colitis was associated with a reduced risk of developing MS (OR=0.969, 95%CI 0.948 to 0.991, P=0.005). ConclusionThe results based on MR analysis suggest that genetically predicted MS is associated with the risk of IBD as a whole and Crohn's disease and ulcerative colitis are associated with a reduced risk of developing MS.
Objective To evaluate and summarize the evidence related to non-pharmacological interventions in community-dwelling elderly with sarcopenia and to provide an evidence-based basis for guiding community health professionals to effectively manage older patients with sarcopenia. Methods We searched all evidence about non-pharmacological interventions in community-dwelling elderly with sarcopenia from BMJ Best Practice, UpToDate, Guidelines International Network, National Institute for Health and Care Excellence, Scottish Intercollegiate Guidelines Network, Registered Nurses' Association of Ontario, Canadian Medical Association Clinical Practice Guidelines Infobase, American Society for Nutrition, Australian JBI Evidence-Based Health Care Centre Database, CINAHL, PubMed, Cochrane Library, Web of Science, CBM, CNKI, WanFang Data and VIP Databases. The types of literature included guidelines, expert consensus, systematic reviews, evidence summaries and meta-analyses. The retrieval time ranged from January 1, 2019 to May 31, 2024. Results A total of 14 publications were included, including 2 guidelines, 3 expert consensuses, and 9 systematic reviews. Twenty-four pieces of evidence were summarized in 3 areas, including screening, assessment, and non-pharmacological interventions for sarcopenia. Conclusion We summarize the best evidence for initial screening, systematic assessment, and comprehensive non-pharmacological interventions for elderly patients with sarcopenia in the community, and provide a guidance and reference for community medical staff to efficiently manage elderly patients with sarcopenia.